Skip to content

Biodesix, Inc. BDSX Free cash flow margin

Free cash flow margin at other companies

NeoGenomics logo
NeoGenomicsNEO
-4.9%
Veracyte logo
VeracyteVCYT
28.7%+11.7pp
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
-10.5%-4.6pp
Personalis, Inc. logo
Personalis, Inc.PSNL
-131.2%-453pp
Guardant Health logo
Guardant HealthGH
-22%-6.7pp
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
-54.5%

Other financials

Income statement

See full
Revenue$25.6M+42.3%
Operating income-$6.2M+32.1%
Net income-$7.8M+29.8%
EPS (diluted)-$0.81+46.7%

Balance sheet

See full
Cash & equivalents$25.6M+45.3%
Total debt$71.6M+15.0%
Total equity$9.1M-17.4%
Total assets$94.6M+9.7%

Cash flow

See full
Operating cash flow-$10.2M-18.2%
CapEx$81.0K+9.5%
Free cash flow-$10.2M-18.1%

Valuation

See full
Market cap$233.52M+476%
Enterprise value$279.56M+204%
P/S2.4×+1.9×

Profitability

See full
Operating margin-26%-7.5pp
Net margin-33.3%-9.3pp

Returns & leverage

See full
Return on equity-316.5%
Debt / equity7.8×+2.2×
Current ratio2.8×+0.6×

Where this comes from

Calculated from Biodesix, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Biodesix, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biodesix, Inc.'s free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biodesix, Inc.'s free cash flow margin?
Biodesix, Inc. (BDSX) reported free cash flow margin of -26.8% in Q1 2026.
How has Biodesix, Inc.'s free cash flow margin changed year-over-year?
Biodesix, Inc.'s free cash flow margin increased by 55.6% year-over-year, from -60.4% to -26.8%.
What is the long-term trend for Biodesix, Inc.'s free cash flow margin?
Over 5 years (2020 to 2025), Biodesix, Inc.'s free cash flow margin has grown at a -11.8% compound annual growth rate (CAGR), from -51.2% to -27.4%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.